- World rank, all time
- #31,639 of 42,892
- Rank in France
- #1,771 of 2,321
- Research works
- 287 ▼ 14% vs 2013–17
- Citations
- 4.8k 16.8 per fractional work
- Top-10% rate
- 11.8% record average 16.5%
- Open access
- 25% world 28%
What is Institut d’Hématologie et d’Oncologie Pédiatrique known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #14,070 of 17,978 | 11.4% | 217 | |
| Health SciencesDomain | #17,191 of 20,462 | 10.9% | 230 |
Each strip is that field’s whole ranked pool, with the notch where Institut d’Hématologie et d’Oncologie Pédiatrique sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.1×. Every wedge is a field page.
- Medicine 4.1×
- Immunology and Microbiology 2.2×
- Biochemistry, Genetics and Molecular Biology 2.1×
- Neuroscience 0.6×
- Health Professions 0.6×
- Pharmacology, Toxicology and Pharmaceutics 0.3×
- Physics and Astronomy 0.3×
- Materials Science 0.1×
- Nursing 0.1×
- Psychology 0.1×
- Social Sciences 0.1×
- Economics, Econometrics and Finance 0.1×
- Engineering 0.1×
- Environmental Science 0.0×
- Business, Management and Accounting 0.0×
- Agricultural and Biological Sciences 0.0×
Who are the top researchers at Institut d’Hématologie et d’Oncologie Pédiatrique?
Ranked on the composite score, P Izarn and Cécile Faure‐Conter lead among researchers whose main affiliation is Institut d’Hématologie et d’Oncologie Pédiatrique.
- 1 P Izarn France · #1,321,280 worldwide 4 citations · 42 works
- 2 Cécile Faure‐Conter France · #1,508,091 worldwide 17 citations · 20 works
Which keywords describe research at Institut d’Hématologie et d’Oncologie Pédiatrique?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Prognostic Factors, Radiotherapy, Molecular Classification, Health-related Quality of Life, Glioblastoma and Temozolomide.
- Pulmonary Hypertension
- Hereditary Angioedema
- Targeted Therapy
- Soft Tissue Sarcoma
- Hematopoietic Stem Cells
- Inflammation
- Childhood Cancer Survivor Study
- Clinical Practice Guidelines
- Glioblastoma
- Molecular Classification
- Cancer
- Radiotherapy
- Immunotherapy
- Chemotherapy
- Prognostic Factors
- Epidemiology
- Health-related Quality of Life
- Genetic Mutations
- Temozolomide
- Thrombosis
- Clinical Trials
- Pediatric Quality of Life Inventory
- Osteosarcoma
- Diagnosis
- Treatment
- Kinin Receptor Family
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 26 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 26 words, with their numbers
- Chemotherapy5▲ 19×16 topics
- Immunotherapy4▲ 18×11 topics
- Prognostic Factors4▲ 26×14 topics
- Radiotherapy2▲ 16×7 topics
- Epidemiology2▲ 1.47×26 topics
- Cancer2▲ 4.1×18 topics
- Health-related Quality of Life2▲ 23×3 topics
- Molecular Classification2▲ 37×4 topics
- Genetic Mutations2▲ 12×13 topics
- Glioblastoma2▲ 78×1 topic
- Temozolomide2▲ 78×1 topic
- Clinical Practice Guidelines2▲ 9.0×6 topics
- Thrombosis2▲ 16×5 topics
- Childhood Cancer Survivor Study2▲ 97×1 topic
- Clinical Trials2▲ 6.3×6 topics
- Inflammation2▲ 2.1×19 topics
- Pediatric Quality of Life Inventory2▲ 97×1 topic
- Hematopoietic Stem Cells1▲ 47×3 topics
- Osteosarcoma1▲ 82×1 topic
- Soft Tissue Sarcoma1▲ 72×1 topic
- Diagnosis1▲ 3.8×10 topics
- Targeted Therapy1▲ 14×3 topics
- Treatment1▲ 2.6×9 topics
- Hereditary Angioedema1▲ 162×1 topic
- Kinin Receptor Family1▲ 162×1 topic
- Pulmonary Hypertension1▲ 22×2 topics
Which research topics does Institut d’Hématologie et d’Oncologie Pédiatrique publish most on?
By volume in 2022–2025: Glioma Diagnosis and Treatment, Childhood Cancer Survivors' Quality of Life, Sarcoma Diagnosis and Treatment and Hemoglobinopathies and Related Disorders.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Glioma Diagnosis and Treatment Genetics 2 works
- 2 Childhood Cancer Survivors' Quality of Life Pediatrics, Perinatology and Child Health 2 works
- 3 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 1 works
- 4 Hemoglobinopathies and Related Disorders Genetics 1 works
- 5 Coagulation, Bradykinin, Polyphosphates, and Angioedema Genetics 1 works
- 6 Neuroblastoma Research and Treatments Neurology 1 works
- 7 Acute Myeloid Leukemia Research Hematology 1 works
- 8 Testicular diseases and treatments Surgery 1 works
- 9 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 1 works
- 10 Blood groups and transfusion Hematology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Institut d’Hématologie et d’Oncologie Pédiatrique's research output changed?
Output in 2018–2022 was 14% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Lyon
- Laboratoire de Chimie
- École Normale Supérieure de Lyon
- Institut National des Sciences Appliquées de Lyon
- Hôpital Edouard Herriot
- Hospices Civils de Lyon
- Université Lumière Lyon 2
- Maison des Sciences sociales et des Humanités - Lyon St-Étienne
- Université Jean Moulin Lyon III
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.